Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet (SCH 39641) in Adults With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (Study P05234)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:
NCT00770315
First received: October 9, 2008
Last updated: June 2, 2014
Last verified: June 2014
  Purpose

This study will evaluate the efficacy and safety of ragweed sublingual tablet (SCH 39641/MK-3641/Amb a 1-U) compared with placebo in participants with ragweed-induced rhinoconjunctivitis over a one-year period. It is expected that ragweed allergic participants on one of the active arms of the trial will have decreased allergic rhinoconjunctivitis symptoms and require less allergy rescue medications during ragweed pollen season.


Condition Intervention Phase
Rhinitis, Allergic
Conjunctivitis
Biological: Ambrosia artemisiifolia allergen extract (Amb a 1-U)
Biological: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet (SCH 39641) in Adult Subjects With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma

Resource links provided by NLM:


Further study details as provided by Merck Sharp & Dohme Corp.:

Primary Outcome Measures:
  • Combined (Sum of) Rhinoconjunctivitis Daily Symptom Score (DSS) and Daily Medication Score (DMS) Averaged Over the Peak Ragweed Season (RS) [ Time Frame: The 15-day period during the ragweed season with the highest moving pollen average ] [ Designated as safety issue: No ]
    The total combined score is a composite endpoint that combines the rhinoconjuntivitis DSS and the rhinoconjunctivitis DMS. The rhinoconjunctivitis DSS consisted of a total of 6 symptoms (runny nose, blocked nose, sneezing, itchy nose, gritty feeling/red/itchy eyes and watery eyes) that were measured on a scale of 0 to 3 (0=no symptoms, 3=severe symptoms; score range: 0-18), with a lower score indicating less rhinoconjunctivitis symptoms. Rhinoconjunctivitis DMS was based on use of specific study-provided rescue medication, with different rescue medications being assigned different scores/dose unit (score range: 0-36), with a lower score indicating less rhinconjunctivitis medication use. The sum of the rhinoconjunctivitis DSS+DMS could range from 0 to 54, with a lower score indicating less rhinoconjuntivitis symptoms and medication use. Raw means were converted to adjusted means using an ANOVA model with baseline asthmatic condition, pollen region and treatment group as fixed effects.


Secondary Outcome Measures:
  • Average Combined Rhinoconjunctivitis DSS and DMS Over the Entire RS [ Time Frame: Approximately 5 weeks ] [ Designated as safety issue: No ]
    The total combined score is a composite endpoint that combines the rhinoconjuntivitis DSS and the rhinoconjunctivitis DMS. The rhinoconjunctivitis DSS consisted of a total of 6 symptoms (runny nose, blocked nose, sneezing, itchy nose, gritty feeling/red/itchy eyes and watery eyes) that were measured on a scale of 0 to 3 (0=no symptoms, 3=severe symptoms; score range: 0-18), with a lower score indicating less rhinoconjunctivitis symptoms. Rhinoconjunctivitis DMS was based on use of specific study-provided rescue medication, with different rescue medications being assigned different scores/dose unit (score range: 0-36), with a lower score indicating less rhinconjunctivitis medication use. The sum of the rhinoconjunctivitis DSS+DMS could range from 0 to 54, with a lower score indicating less rhinoconjuntivitis symptoms and medication use. Raw means were converted to adjusted means using an ANOVA model with baseline asthmatic condition, pollen region and treatment group as fixed effects.

  • Average Rhinoconjunctivitis DSS for the Peak RS [ Time Frame: The 15-day period during the ragweed season with the highest moving pollen average ] [ Designated as safety issue: No ]
    The rhinoconjunctivitis DSS consisted of a total of 6 symptoms (runny nose, blocked nose, sneezing, itchy nose, gritty feeling/red/itchy eyes and watery eyes) that were measured on a scale of 0 to 3 (0=no symptoms, 3=severe symptoms; score range: 0-18), with a lower score indicating less rhinoconjunctivitis symptoms. Raw means were converted to adjusted means using an ANOVA model with baseline asthmatic condition, pollen region and treatment group as fixed effects.

  • Average Rhinoconjunctivitis DSS for the Entire RS [ Time Frame: Approximately 5 weeks ] [ Designated as safety issue: No ]
    The rhinoconjunctivitis DSS consisted of a total of 6 symptoms (runny nose, blocked nose, sneezing, itchy nose, gritty feeling/red/itchy eyes and watery eyes) that were measured on a scale of 0 to 3 (0=no symptoms, 3=severe symptoms; score range: 0-18), with a lower score indicating less rhinoconjunctivitis symptoms. Raw means were converted to adjusted means using an ANOVA model with baseline asthmatic condition, pollen region and treatment group as fixed effects.

  • Average Rhinoconjunctivitis DMS for the Peak RS [ Time Frame: The 15-day period during the ragweed season with the highest moving pollen average ] [ Designated as safety issue: No ]
    Rhinoconjunctivitis DMS was based on participant use of specific study-provided rescue medication, with different rescue medications being assigned different scores/dose unit (score range: 0-36), with a lower score indicating less rhinconjunctivitis medication use. Raw means were converted to adjusted means using an ANOVA model with baseline asthmatic condition, pollen region and treatment group as fixed effects.


Enrollment: 784
Study Start Date: September 2009
Study Completion Date: May 2011
Primary Completion Date: May 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: SCH 39641 1.5 Amb a 1-U
Participants receive Ambrosia artemisiifolia allergan extract (SCH 39641 1.5 Amb a 1-U) rapidly dissolving sublingual tablets, administered once daily for approximately 52 weeks
Biological: Ambrosia artemisiifolia allergen extract (Amb a 1-U)
Rapidly dissolving tablet administered sublingually once daily, at a dose of 1.5, 6 or 12 units.
Other Names:
  • SCH 39641
  • MK-3641
Experimental: SCH 39641 6 Amb a 1-U
Participants receive Ambrosia artemisiifolia allergan extract (SCH 39641 6 Amb a 1-U) rapidly dissolving sublingual tablets, administered once daily for approximately 52 weeks
Biological: Ambrosia artemisiifolia allergen extract (Amb a 1-U)
Rapidly dissolving tablet administered sublingually once daily, at a dose of 1.5, 6 or 12 units.
Other Names:
  • SCH 39641
  • MK-3641
Experimental: SCH 39641 12 Amb a 1-U
Participants receive Ambrosia artemisiifolia allergan extract (SCH 39641 12 Amb a 1-U) rapidly dissolving sublingual tablets, administered once daily for approximately 52 weeks
Biological: Ambrosia artemisiifolia allergen extract (Amb a 1-U)
Rapidly dissolving tablet administered sublingually once daily, at a dose of 1.5, 6 or 12 units.
Other Names:
  • SCH 39641
  • MK-3641
Placebo Comparator: Placebo
Participants receive matching placebo rapidly dissolving sublingual tablets, administered once daily for approximately 52 weeks
Biological: Placebo
Placebo matching Ambrosia artemisiifolia allergen extract rapidly dissolving tablet, administered sublingually once daily

  Eligibility

Ages Eligible for Study:   18 Years to 50 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Must have a clinical history of significant ragweed-induced allergic rhinoconjunctivitis of at least 2 years duration, with or without asthma and have received treatment during the previous ragweed season (RS).
  • Must have a positive skin prick test response to Ambrosia artemisiifolia at Screening Visit.
  • Must be positive for specific immunoglobulin E (IgE) against Ambrosia artemisiifolia at Screening Visit.
  • Must have an forced expiratory volume in one second (FEV1) of at least 70% of predicted at Screening Visit.
  • Safety laboratory tests and vital signs conducted at the Screening Visit must be within normal limits or clinically acceptable to the investigator/sponsor.
  • Must be willing to give written informed consent and be able to adhere to dose and visit schedules.
  • Female participants of childbearing potential must be using a medically acceptable and adequate form of birth control. These include: hormonal contraceptives as prescribed by a physician (oral, hormonal vaginal ring, hormonal implant or depot injectable); medically prescribed intra-uterine device; medically prescribed topically-applied transdermal contraceptive patch; double-barrier method (eg, condom in combination with a spermicide).
  • Female participants of childbearing potential should be counseled in the appropriate use of birth control while in the study. Female participants who are not currently sexually active must and consent to use one of the above-mentioned methods if she becomes sexually active during the study.
  • Female participants of childbearing potential must have a negative urine pregnancy test at Screening Visit. Women who have been surgically sterilized or at least 1 year postmenopausal are not considered to be of childbearing potential.

Exclusion Criteria:

  • Clinical history of symptomatic seasonal allergic rhinitis and/or asthma having received regular medication, due to another during or potentially overlapping the RS.
  • Clinical history of significant symptomatic perennial allergic rhinitis and/or asthma due to an allergen to which the participant is regularly exposed.
  • Receipt of an immunosuppressive treatment within 3 months prior to the Screening Visit (except steroids for allergic and asthma symptoms).
  • Clinical history of severe asthma.
  • Asthma requiring medium or high dose inhaled corticosteroids (ICS).
  • History of anaphylaxis with cardiorespiratory symptoms.
  • History of chronic urticaria and angioedema.
  • Clinical history of chronic sinusitis 2 years prior to the Screening Visit.
  • Current severe atopic dermatitis.
  • Breast-feeding, pregnancy, or intending to become pregnant.
  • Had previous treatment by immunotherapy with ragweed allergen or any other allergen 5 years prior to Screening Visit.
  • History of allergy, hypersensitivity or intolerance to the ingredients of the investigational medicinal products (except for Ambrosia artemisiifolia), rescue medications, or self-injectable epinephrine.
  • Any clinically significant condition or situation, other than the condition being studied that, in the opinion of the investigator, would interfere with the study evaluations or optimal participation in the study.
  • Use of any investigational drugs within 30 days of Screening Visit.
  • Participation in any other clinical study.
  • Being a family member of the study staff.
  • Inability to meet medication washout requirements.
  • Unlikely to be able to complete the trial, or likely to travel for an extended time during the RS.
  • Clinically significant abnormal vital sign or lab value.
  • Participation in this same study at another site.
  • Randomized into this study more than once.
  • Inability to or will not comply with the use of self-injectable epinephrine.
  • Greater risk of developing adverse reactions after epinephrine administration.
  • History of self-injectable epinephrine use
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

No publications provided by Merck Sharp & Dohme Corp.

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier: NCT00770315     History of Changes
Other Study ID Numbers: P05234, 3810249, 2008-003864-20, MK-3641-002
Study First Received: October 9, 2008
Results First Received: April 25, 2014
Last Updated: June 2, 2014
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Conjunctivitis
Conjunctival Diseases
Eye Diseases

ClinicalTrials.gov processed this record on October 23, 2014